Amazon's blockbuster quarter just injected a massive dose of relief into the AI trade, providing the exact proof of monetization the market has been demanding. Coupled with the forced liquidation of a prominent, highly leveraged hedge fund—an event that structurally explains much of this week's violent momentum unwind—the overhang on semiconductor infrastructure is suddenly lifting.
Amazon (AMZN) shares surged 9% in overnight trading after its Q2 earnings shattered expectations. The primary catalyst was a 37% acceleration in Amazon Web Services (AWS) revenue growth, its fastest in 18 quarters, with total company revenue hitting $200.6 billion. The blowout performance eased investor concerns about the high cost of AI capital expenditures and negative free cash flow, providing powerful validation that its AI spending is translating directly to the top line.
Why it matters
Amazon's results are a major sentiment shifter for the entire AI ecosystem. After a week of anxiety over capex, this report proves that hyperscale AI investment can yield immediate, massive revenue growth, not just burn cash. This provides a strong bullish read-through for the entire AI infrastructure and semiconductor space, offering a clear long setup for AMZN and lifting related names like MU and SMCI in sympathy.
Reddit (RDDT) stock dropped 10% in overnight trading despite reporting a stellar quarter. The company posted a significant earnings beat with revenue up 61% to $805 million and issued strong Q3 guidance. However, the positive results were completely overshadowed by investor fears over slowing U.S. user growth and the existential threat of Google's AI Overviews siphoning away referral traffic, a core part of Reddit's user acquisition model.
Why it matters
This is a quintessential 'sell the news' reaction where a structural headwind obliterates strong current results. The market is looking past the strong print and pricing in a fundamental threat to Reddit's future growth engine. The technical breakdown on heavy volume makes RDDT a compelling short candidate, as the narrative shifts from growth story to a company facing a powerful new competitor in Google's AI.
Silicon Motion Technology (SIMO) gapped up Thursday after reporting a massive Q2 earnings beat and raising its full-year outlook. The company posted EPS of $2.43 (vs. $2.13 consensus) on revenue of $451 million, which grew 127% year-over-year. Management cited broad-based product momentum and expansion into the AI PC, automotive, and data center markets as key drivers.
Why it matters
SIMO's report provides a clear long candidate for a continuation trade. A triple-digit revenue growth rate combined with a guidance raise points to strong fundamental momentum and institutional sponsorship. The stock's gap-up is a direct reaction to the market repricing the company's growth prospects, particularly its successful expansion into high-demand AI-related end markets.
The mean reversion setup we've tracked in Micron (MU) triggered an 18% relief rally on Friday, powerfully rebounding from its recent 41% correction. The catalyst was commentary from competitor Samsung's Q2 earnings report, which confirmed a long-term memory supply shortage driven by insatiable AI demand, projecting the imbalance could last until 2028. This directly counters the recent bear thesis of a supply glut and rising Chinese competition, leading to a wave of analyst upgrades and a technical breakout for Micron above its 50-day EMA.
Why it matters
This is a significant episodic pivot for Micron and the memory sector. The narrative has shifted from a cyclical downturn to a structural, multi-year tailwind from AI. The combination of a fundamental catalyst (Samsung's forecast), bullish analyst actions (BofA adding MU to its US 1 List), and a clean technical breakout from an oversold base presents a high-conviction long setup for swing traders.
Validating its position as a key beneficiary in the AI power rotation we've highlighted, Bloom Energy (BE) exploded over 25% on Thursday after crushing Q2 expectations and significantly raising its full-year 2026 guidance. BE reported adjusted EPS of $0.78 (vs. $0.41 consensus) on revenue of $1.07B (vs. $827M consensus), driven by strong data center demand and underscored by a new $1.7 billion power deal with AI firm Nebius.
Why it matters
This is a classic episodic pivot, confirming Bloom's central role as a 'picks and shovels' play for the AI infrastructure buildout. The combination of a huge earnings and guidance beat with a major new contract win provides a powerful fundamental catalyst. For traders, the stock's massive gap-up on high volume signals strong institutional sponsorship and a potential continuation move. Mizuho upgraded the stock to Buy following the print.
Semiconductor testing supplier FormFactor (FORM) soared 25.76% on Thursday after delivering record Q2 revenue of $258.2M and EPS of $0.82, crushing the $0.61 consensus. Crucially, the company guided Q3 well above expectations, projecting EPS of $0.86 (vs. $0.62 consensus), citing powerful demand for DRAM, foundry, and advanced packaging probes used in AI and HPC applications.
Why it matters
This 'beat and raise' constitutes a major episodic pivot, signaling that FormFactor is a key beneficiary of the AI hardware buildout. The stock broke out of a multi-month base on massive volume, a textbook technical setup for momentum traders. The strong guidance confirms its leverage to the most critical, and currently supply-constrained, parts of the semiconductor supply chain like HBM and advanced packaging.
Corcept Therapeutics (CORT) gapped up over 28% on Thursday after reporting Q2 EPS of $0.36, blowing past the $0.05 consensus estimate. Revenue also beat significantly at $256.1 million versus a $220.1 million expectation. The company raised its full-year 2026 revenue guidance to $1.1B–$1.2B, crediting strong momentum from its oncology drug Lifyorli and continued growth in its Cushing’s syndrome franchise.
Why it matters
This is a pure, catalyst-driven episodic pivot. The massive earnings surprise and subsequent guidance raise represent a fundamental story change that the market was not anticipating. The stock's powerful gap-up and hold at higher levels on significant volume indicate strong institutional buying interest, creating a clear long setup for momentum and breakout traders.
In a significant reversal, an FDA advisory committee voted 10-3 in favor of Replimune's (REPL) experimental melanoma treatment, RP1. The positive recommendation came despite an earlier, more skeptical briefing document from FDA staff that had raised concerns about the trial data. The vote significantly increases the likelihood of a full FDA approval by the drug's August 2 PDUFA date. Following the vote, Cantor Fitzgerald upgraded the stock to Overweight.
Why it matters
This positive AdCom vote is a major de-risking event for Replimune, snatching victory from the jaws of a potential regulatory defeat. It's a classic catalyst-driven setup for traders. The market had priced in significant risk after the negative staff review, and this sharp reversal creates an immediate opportunity as the stock is repriced to reflect a much higher probability of approval.
Alnylam Pharmaceuticals (ALNY) shares crashed 28% on Thursday after the company unexpectedly slashed its 2026 revenue forecast for its flagship drug, Amvuttra. The biotech lowered its full-year TTR product revenue outlook to a range of $4.2 billion to $4.5 billion, a significant reduction from the prior $4.4 billion to $4.7 billion guidance, citing a 'reassessment of demand dynamics.'
Why it matters
A guidance cut on a company's main growth driver is one of the most potent negative catalysts in biotech. This move signals a major crack in what was perceived as a solid growth story, triggering a violent repricing of the stock. For traders, this creates a high-conviction short opportunity, as the market digests the new, weaker growth trajectory and questions the drug's long-term potential.
We now have a name for the forced de-grossing that fueled Wednesday's violent momentum unwind: Leopold Aschenbrenner's 'Situational Awareness LP' hedge fund. After being up 439% through June, the $20 billion fund blew up due to extreme (~4x) leverage on concentrated AI infrastructure longs and enterprise software shorts. A 25% portfolio drawdown triggered cascading margin calls, forcing a fire sale of its entire public equity book—both longs and shorts—to Citadel, a liquidation reportedly accelerated by other funds 'hunting' its known positions.
Why it matters
Pinpointing the source of this week's panic flush confirms it was a market-moving technical dislocation rather than a fundamental breakdown. The removal of this massive forced seller is a significant catalyst in its own right. With the overhang gone, AI infrastructure stocks that were artificially depressed now have a clearer path to rebound, creating potential long setups in names that were caught in the crossfire.
Following yesterday's Baird downgrade over New York data center moratorium risks, shares of Caterpillar (CAT) have extended their pullback and are now approaching a critical technical support confluence. The stock is nearing its 200-day Exponential Moving Average at $754.36 and the 78.6% Fibonacci retracement level of its recent up-move at $752.07, representing a potential zone for buyers to step in.
Why it matters
This presents a potential mean-reversion long setup in a high-quality industrial leader. For tactical traders, a confluence of major technical support levels like a 200-day MA and a key Fibonacci level provides a well-defined, low-risk entry point to play for a bounce. The trade thesis is invalidated on a clean break and close below this support zone.
Following yesterday's test of the 7,555 gamma flip level, U.S. stock futures are pointing to a higher open, driven by Amazon's strong earnings. A detailed Goldman Sachs flow desk report notes that while institutional leverage remains high, positioning is cleaner after this week's liquidations. Buybacks remain the primary source of equity demand. For the S&P 500, key tactical levels are in play, with gamma flip points and VWAP acting as support and resistance, while bearish retail sentiment persists on SPY per Stocktwits data.
Why it matters
This provides a tactical map for the day's trading. The combination of futures direction, key S&P 500 levels from options markets, and detailed institutional flow analysis from Goldman offers precise levels for entries, exits, and risk management. Knowing that buybacks are the main support while passive inflows are tapering is crucial context for understanding market structure and potential volatility.
Amazon Earnings Revive AI Hardware Trade Amazon's spectacular 37% AWS growth and strong revenue beat have single-handedly pulled the semiconductor and AI infrastructure sectors out of their recent rout. The results validate the massive capex spend, assuaging investor fears and triggering a sharp rebound in names like Micron, while drawing a stark contrast with Apple's weaker outlook.
Forced Liquidation Clears Major Seller From AI Stocks The catastrophic collapse of Leopold Aschenbrenner's highly leveraged 'Situational Awareness' hedge fund, culminating in a forced fire sale of its entire public portfolio to Citadel, has removed a massive, technically-driven seller from the market. The rebound in AI infrastructure stocks suggests the recent sell-off was driven more by this liquidation than a fundamental shift, potentially setting up a new leg higher.
The Great Divergence in Big Tech Earnings This week's earnings have split the tech giants into two camps. Companies demonstrating clear AI revenue streams, like Amazon and Microsoft, are being rewarded with soaring stock prices. In contrast, those showing slowing growth or facing external threats, like Apple and Reddit, are being punished, highlighting the market's new focus on proven monetization over speculative promise.
Biotech Catalysts Deliver Binary Outcomes The FDA advisory committee process delivered sharply contrasting results. Replimune's melanoma drug RP1 received a positive recommendation, increasing its odds of approval and sending the stock higher. Conversely, Capricor's Duchenne therapy was rejected by the panel, causing its shares to plummet and underscoring the high-stakes, binary nature of biotech regulatory events.
Capital Rotates to India as AI Trade De-Risks Global investors are rotating capital out of crowded North American and Asian AI-linked tech stocks and into markets with less direct AI exposure, with India emerging as a key beneficiary. Indian IT and broader market indices are outperforming as investors seek diversification and value away from the volatile semiconductor sector.
What to Expect
Aug 2—PDUFA date for Replimune's (REPL) RP1 melanoma treatment.
Aug 2—U.S. July Jobs Report (NFP) is scheduled for release, a key data point for the Fed's September rate decision.
Aug 22—PDUFA target action date for Capricor's (CAPR) Duchenne cell therapy, Deramiocel.
Early August—Key economic data releases including ISM PMIs, JOLTs Job Openings, and Unemployment Rate.
How We Built This Briefing
Every story, researched.
Every story verified across multiple sources before publication.
🔍
Scanned
Across multiple search engines and news databases
618
📖
Read in full
Every article opened, read, and evaluated
198
⭐
Published today
Ranked by importance and verified across sources
12
— The Tape Reader
🎙 Listen as a podcast
Subscribe in your favorite podcast app to get each new briefing delivered automatically as audio.
Apple Podcasts
Library tab → ••• menu → Follow a Show by URL → paste